NYSE · CON
Concentra Group Holdings Parent, Inc.
$41.25+$0.66 (+1.63%)
Concentra Group Holdings Parent, Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.29% below the high.
Loading market information…
NYSE · HAE · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Haemonetics Corporation’s quoted price sits in the upper half of its reported 52-week range, 3.22% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Haemonetics Corporation’s next earnings report is currently expected on Nov 5, 2026, with estimated earnings per share of $1.29. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Haemonetics Corporation’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Haemonetics Corporation is a healthcare enterprise dedicated to providing medical products and comprehensive solutions, structured into three main business areas: Plasma, Blood Center, and Hospital. In its Plasma segment, the company develops automated plasma collection systems, exemplified by the NexSys PCS and PCS2 devices, along with necessary disposables and intravenous solutions. It also offers integrated information technology platforms and the NexLynk DMS donor management system to help plasma customers efficiently manage their donors, operations, and supply chains. The Blood Center division provides advanced automated blood component and manual whole blood collection technologies. This includes MCS brand apheresis equipment for selectively collecting blood components, as well as disposable kits for whole blood collection and storage. Its software offerings feature the SafeTrace Tx blood bank information system and BloodTrack, a sophisticated suite of blood management software and hardware designed to enhance hospital blood bank functionalities and facilitate bedside transfusions. For the Hospital sector, Haemonetics offers hemostasis analyzer systems like TEG, ClotPro, and HAS, which deliver crucial assessments of a patient's overall clotting ability. The TEG Manager software links these analyzers throughout a facility, enabling clinicians to remotely access active and past test results to inform treatment decisions. Additionally, the Cell Saver Elite+ system supports autologous blood recovery across a wide range of surgical procedures, including cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological operations. The company distributes its products and solutions through its own direct sales teams, independent distributors, and sales representatives. Haemonetics Corporation was established in 1971 and is based in Boston, Massachusetts.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 02:32 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q4 2025 | May 8, 2025 | $1.24+1.64% vs estimate | $330.60M+5.8% vs estimate |
|---|
| Q3 2025 | Feb 6, 2025 | $1.19+0.85% vs estimate | $348.54M-1.67% vs estimate |
|---|
| Q2 2025 | Nov 7, 2024 | $1.12+2.75% vs estimate | $345.51M+0.83% vs estimate |
|---|
THE ANALYST VIEW
21 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
Consensus coverage: 5 contributors · Median target $130.00.
Average targets in published notes for each window. These figures use a different sample from the consensus above.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$41.25+$0.66 (+1.63%)
Concentra Group Holdings Parent, Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.29% below the high.
$126.52-$0.03 (-0.02%)
Integer Holdings Corporation’s quoted price sits in the upper half of its reported 52-week range, 0.24% below the high.
$31.49$0.00 (0.0%)
Catalyst Pharmaceuticals, Inc.’s quoted price sits in the upper half of its reported 52-week range, 3.29% below the high.
$8.91+$1.99 (+28.76%)
Bausch Health Companies Inc.’s quoted price sits in the upper half of its reported 52-week range, 1.44% below the high.
$24.59+$0.16 (+0.65%)
Warby Parker Inc.’s quoted price sits in the upper half of its reported 52-week range, 20.68% below the high.
$28.84+$0.06 (+0.21%)
Beam Therapeutics Inc.’s quoted price sits in the lower half of its reported 52-week range, 24.62% below the high.
$85.27+$2.40 (+2.9%)
LeMaitre Vascular, Inc.’s quoted price sits in the lower half of its reported 52-week range, 27.74% below the high.
$9.61+$0.17 (+1.8%)
DENTSPLY SIRONA Inc.’s quoted price sits in the lower half of its reported 52-week range, 34.89% below the high.
